These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33941543)

  • 1. Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved
    Li J; Liu J; Zhang X; Clausen V; Tran C; Arciprete M; Wang Q; Rocca C; Guan LH; Zhang G; Najarian D; Xu Y; Smith P; Wu JT; Chong S
    Drug Metab Dispos; 2021 Jul; 49(7):572-580. PubMed ID: 33941543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Givosiran: First Approval.
    Scott LJ
    Drugs; 2020 Feb; 80(3):335-339. PubMed ID: 32034693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.
    Vassiliou D; Sardh E; Harper P; Simon AR; Clausen VA; Najafian N; Robbie GJ; Agarwal S
    Clin Pharmacol Ther; 2021 Nov; 110(5):1250-1260. PubMed ID: 34510420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Givosiran: A Review in Acute Hepatic Porphyria.
    Syed YY
    Drugs; 2021 May; 81(7):841-848. PubMed ID: 33871817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New therapeutic option for acute hepatic porphyrias].
    Stölzel U; Schuppan D
    Dtsch Med Wochenschr; 2021 Aug; 146(15):955-958. PubMed ID: 34344029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria.
    Agarwal S; Simon AR; Goel V; Habtemariam BA; Clausen VA; Kim JB; Robbie GJ
    Clin Pharmacol Ther; 2020 Jul; 108(1):63-72. PubMed ID: 31994716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Absorption, Distribution, Metabolism and Excretion of RGLS4326 in Mouse and Monkey, an Anti-miR-17 Oligonucleotide for the Treatment of Polycystic Kidney Disease.
    Kamel A; Owen T; Cole I; Valencia T; Lee EC
    Drug Metab Dispos; 2023 Nov; 51(11):1536-1546. PubMed ID: 37643880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.
    de Paula Brandão PR; Titze-de-Almeida SS; Titze-de-Almeida R
    Mol Diagn Ther; 2020 Feb; 24(1):61-68. PubMed ID: 31792921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of
    McDougall R; Ramsden D; Agarwal S; Agarwal S; Aluri K; Arciprete M; Brown C; Castellanos-Rizaldos E; Charisse K; Chong S; Cichocki J; Fitzgerald K; Goel V; Gu Y; Guenther D; Habtemariam B; Jadhav V; Janas M; Jayaraman M; Kurz J; Li J; Liu J; Liu X; Liou S; Maclauchlin C; Maier M; Manoharan M; Nair JK; Robbie G; Schmidt K; Smith P; Theile C; Vaishnaw A; Waldron S; Xu Y; Zhang X; Zlatev I; Wu JT
    Drug Metab Dispos; 2022 Jun; 50(6):781-797. PubMed ID: 34154993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria.
    Sardh E; Harper P; Balwani M; Stein P; Rees D; Bissell DM; Desnick R; Parker C; Phillips J; Bonkovsky HL; Vassiliou D; Penz C; Chan-Daniels A; He Q; Querbes W; Fitzgerald K; Kim JB; Garg P; Vaishnaw A; Simon AR; Anderson KE
    N Engl J Med; 2019 Feb; 380(6):549-558. PubMed ID: 30726693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy.
    Majeed CN; Ma CD; Xiao T; Rudnick S; Bonkovsky HL
    Drug Des Devel Ther; 2022; 16():1827-1845. PubMed ID: 35734365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Givosiran for the treatment of acute hepatic porphyria.
    Ricci A; Ventura P
    Expert Rev Clin Pharmacol; 2022 Apr; 15(4):383-393. PubMed ID: 35531651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
    Balwani M; Sardh E; Ventura P; Peiró PA; Rees DC; Stölzel U; Bissell DM; Bonkovsky HL; Windyga J; Anderson KE; Parker C; Silver SM; Keel SB; Wang JD; Stein PE; Harper P; Vassiliou D; Wang B; Phillips J; Ivanova A; Langendonk JG; Kauppinen R; Minder E; Horie Y; Penz C; Chen J; Liu S; Ko JJ; Sweetser MT; Garg P; Vaishnaw A; Kim JB; Simon AR; Gouya L;
    N Engl J Med; 2020 Jun; 382(24):2289-2301. PubMed ID: 32521132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonclinical Pharmacokinetics Study of OLX702A-075-16,
    Ban J; Seo BK; Yu Y; Kim M; Choe J; Park JH; Park SY; Lee DK; Kim SH
    Drug Metab Dispos; 2024 Oct; 52(11):1262-1270. PubMed ID: 39168524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study.
    Sardh E; Balwani M; Rees DC; Anderson KE; Jia G; Sweetser MT; Wang B
    Orphanet J Rare Dis; 2024 Oct; 19(1):365. PubMed ID: 39363243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
    Sardh E; Harper P
    J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?
    Petrides PE; Klein M; Schuhmann E; Torkler H; Molitor B; Loehr C; Obermeier Z; Beykirch MK
    Ann Hematol; 2021 Jul; 100(7):1685-1693. PubMed ID: 34050373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.
    Ventura P; Bonkovsky HL; Gouya L; Aguilera-Peiró P; Montgomery Bissell D; Stein PE; Balwani M; Anderson DKE; Parker C; Kuter DJ; Monroy S; Oh J; Ritchie B; Ko JJ; Hua Z; Sweetser MT; Sardh E;
    Liver Int; 2022 Jan; 42(1):161-172. PubMed ID: 34717041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Givosiran to treat acute porphyria.
    Honor A; Rudnick SR; Bonkovsky HL
    Drugs Today (Barc); 2021 Jan; 57(1):47-59. PubMed ID: 33594389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, placebo-controlled study of givosiran in patients with acute hepatic porphyrias (ENVISION): Final (36-month) analysis of the Taiwan Cohort.
    Lee MJ; Kuo HC; Chou LN; Sweetser MT; Wang JD
    J Formos Med Assoc; 2024 Jun; 123(6):679-686. PubMed ID: 38044204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.